PRNewsWire·1d ago
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent SurgeryNew Category Will Introduce a Closed-Loop Framework: Predict. Perform. Recover.
ZBH's revenue growth has decelerated from 9.7% year over year in 2025Q3 to 3.1% in 2026Q3, and quarterly gross margin has swung between 64.7% and 72.4%, which suggests the recovery narrative remains unproven.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has slowed to 3.1% in 2026Q3 from 9.7% a year earlier while operating margin held at 14.9% and net margin fell to 9.3% against 13.7% in 2024Q3, indicating that SG&A of $855.0M continues to absorb much of the gross profit gains.
Zimmer Biomet is a global leader in orthopedic reconstructive implants, with strong positions in knee, hip, and shoulder replacements.
The company is advancing into higher-tech tools like robotics, data, and smart implants, as seen with the ROSA-assisted outpatient shoulder milestone.
Zimmer Biomet has demonstrated robust free cash flow generation, supporting its financial flexibility and shareholder returns.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $1.90+1.1% vs $1.88 | $2.1B+1.1% vs $2.0B |
Q3 2026 Aug 5, 2026 | $2.07+3.0% vs $2.01 | $2.2B+2.0% vs $2.1B |
Q2 2026 Apr 28, 2026 | $2.09+12.4% vs $1.86 | $2.1B+0.8% vs $2.1B |
Q1 2026 Feb 10, 2026 | $2.42+1.7% vs $2.38 | $2.2B+0.9% vs $2.2B |
New Category Will Introduce a Closed-Loop Framework: Predict. Perform. Recover.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zimmer Biomet Holdings (NYSE:ZBH) stock is trading at a 52-week high after the better-than-expected third-quarter earnings.
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript
Benchmark ZBH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zimmer Biomet Holdings, Inc. (ZBH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $42.75 | $63.54B | 17.79 | 19.87% | 16.56% | 13.74% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $31.15 | $13.08B | 21.63 | 6.09% | — | — | 2.43% | |
| $71.05 | $9.58B | 17.33 | 16.65% | 17.76% | 11.82% | — |
Zimmer Biomet Holdings, Inc. (ZBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zimmer Biomet Holdings, Inc. (ZBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 5, 2026·SEC
Aug 5, 2026·SEC
Get notified when ZBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zimmer Biomet Holdings, Inc. (ZBH) stock FAQ — growth, dividends, profitability & financials explained
Zimmer Biomet Holdings, Inc. (ZBH) reported $8.57B in revenue over the trailing twelve months. Revenue was $8.23B in fiscal year 2025. That is 777% more than the $939.0M of fiscal year 1999.
Zimmer Biomet Holdings, Inc. (ZBH) grew revenue by 7.0% over the trailing twelve months, compared with the twelve months before.
Yes. Zimmer Biomet Holdings, Inc. (ZBH) earned $767.5M in net income over the trailing twelve months (a 9.0% net margin).
Yes. Zimmer Biomet Holdings, Inc. (ZBH) pays a dividend that yields 0.91% at the current price, a small yield.
Zimmer Biomet Holdings, Inc. (ZBH) had a return on equity (ROE) of 6.1% over the trailing twelve months. That is below the market's typical 10-15%.
Zimmer Biomet Holdings, Inc. (ZBH) generated $1.66B in free cash flow over the trailing twelve months.
